Investors - Press Releases
|View printer-friendly version|
Tabula Rasa HealthCare’s DoseMe® Bayesian Forecasting Method Receives Rating of Most User-Friendly in Clinical Study
BF programs, such as DoseMeRx, use patient data and laboratory results to estimate a patient’s ability to process a drug. Using a published population model, the program adjusts the pharmacokinetic parameters and provides an individualized dosing recommendation to reach a therapeutic target.
Published in the
“A potential barrier to the use of the Bayesian forecasting method of dose individualization is the availability of an easy-to-use program,” said TRHC Chairman and CEO
This is the first ever user-friendly evaluation of these programs with end-users, according to the BJCP article titled, “An Evaluation of the User-friendliness of Bayesian Forecasting in a Clinical Setting.”
“DoseMeRx was the favored software across all user-friendly categories, most notably in the ease of data entry and clarity of understanding and interpreting recommendations presented,” stated DoseMe CEO
DoseMe’s precision dosing software, DoseMeRx, was developed specifically for clinical practice. It is a simple, yet powerful tool helping healthcare providers calculate the optimal dose of drugs monitored by therapeutic drug monitoring to streamline operations, reduce adverse drug events, decrease costs, and improve patient outcomes.
DoseMe is a
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the
T: (443) 213-0500
Source: Tabula Rasa HealthCare, Inc.